Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Rexahn Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Rexahn Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Rexahn Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Rexahn Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Rexahn Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Rexahn Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Rexahn Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Rexahn Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Rexahn Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Rexahn Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Rexahn Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Rexahn Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Rexahn Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Rexahn Pharmaceuticals, Inc. Snapshot 5 Rexahn Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Rexahn Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Rexahn Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Rexahn Pharmaceuticals, Inc. - Pipeline Products Glance 11 Rexahn Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Rexahn Pharmaceuticals, Inc. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Rexahn Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 14 Unknown Products/Combination Treatment Modalities 14 Rexahn Pharmaceuticals, Inc. - Drug Profiles 15 RX-0201 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 RX-3117 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 RX-5902 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 RX-0047N 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 RX-0201N 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 RX-1792 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 RX-21101 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 RX-8243 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Rexahn Pharmaceuticals, Inc. - Pipeline Analysis 24 Rexahn Pharmaceuticals, Inc. - Pipeline Products by Target 24 Rexahn Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 26 Rexahn Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 27 Rexahn Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 28 Rexahn Pharmaceuticals, Inc. - Recent Pipeline Updates 30 Rexahn Pharmaceuticals, Inc. - Dormant Projects 37 Rexahn Pharmaceuticals, Inc. - Locations And Subsidiaries 38 Head Office 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables Rexahn Pharmaceuticals, Inc., Key Information 5 Rexahn Pharmaceuticals, Inc., Key Facts 5 Rexahn Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Rexahn Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Rexahn Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Rexahn Pharmaceuticals, Inc. - Phase II, 2014 11 Rexahn Pharmaceuticals, Inc. - Phase I, 2014 12 Rexahn Pharmaceuticals, Inc. - Preclinical, 2014 13 Rexahn Pharmaceuticals, Inc. - Unknown, 2014 14 Rexahn Pharmaceuticals, Inc. - Pipeline by Target, 2014 25 Rexahn Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 26 Rexahn Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 27 Rexahn Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 29 Rexahn Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 30 Rexahn Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.